AJP - Endo Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 293: E1716-E1725, 2007. First published September 25, 2007; doi:10.1152/ajpendo.00459.2007
0193-1849/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/6/E1716    most recent
00459.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Limesand, S. W.
Right arrow Articles by Hay, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Limesand, S. W.
Right arrow Articles by Hay, W. W., Jr.

Increased insulin sensitivity and maintenance of glucose utilization rates in fetal sheep with placental insufficiency and intrauterine growth restriction

Sean W. Limesand,2 Paul J. Rozance,1 Danielle Smith,1 and William W. Hay, Jr.1

1Perinatal Research Center, Department of Pediatrics, University of Colorado Health Sciences Center, Aurora, Colorado; and 2Agricultural Research Complex, Department of Animal Sciences, University of Arizona, Tucson, Arizona

Submitted 17 July 2007 ; accepted in final form 23 September 2007


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
In this study we determined body weight-specific fetal (umbilical) glucose uptake (UGU), utilization (GUR), and production rates (GPR) and insulin action in intrauterine growth-restricted (IUGR) fetal sheep. During basal conditions, UGU from the placenta was 33% lower in IUGR fetuses, but GUR was not different between IUGR and control fetuses. The difference between glucose utilization and UGU rates in the IUGR fetuses demonstrated the presence and rate of fetal GPR (41% of GUR). The mRNA concentrations of the gluconeogenic enzymes glucose-6-phophatase and PEPCK were higher in the livers of IUGR fetuses, perhaps in response to CREB activation, as phosphorylated CREB/total CREB was increased 4.2-fold. A hyperglycemic clamp resulted in similar rates of glucose uptake and utilization in IUGR and control fetuses. The nearly identical GURs in IUGR and control fetuses at both basal and high glucose concentrations occurred at mean plasma insulin concentrations in the IUGR fetuses that were ~70% lower than controls, indicating increased insulin sensitivity. Furthermore, under basal conditions, hepatic glycogen content was similar, skeletal muscle glycogen was increased 2.2-fold, the fraction of fetal GUR that was oxidized was 32% lower, and GLUT1 and GLUT4 concentrations in liver and skeletal muscle were the same in IUGR fetuses compared with controls. These results indicate that insulin-responsive fetal tissues (liver and skeletal muscle) adapt to the hypoglycemic-hypoinsulinemic IUGR environment with mechanisms that promote glucose utilization, particularly for glucose storage, including increased insulin action, glucose production, shunting of glucose utilization to glycogen production, and maintenance of glucose transporter concentrations.

pregnancy; fetus; glucose oxidation

NUMEROUS HUMAN EPIDEMIOLOGICAL STUDIES (8, 36, 37, 62) have linked poor prenatal growth resulting from fetal nutrient deficiencies to diseases later in life that are associated with insulin resistance and the metabolic syndrome. The "thrifty phenotype" hypothesis was proposed by Hales et al. (37) to explain how poor nutrition in early life could initiate a sparing response through adaptations in insulin secretion, insulin action, and glucose metabolism to benefit perinatal survival. After birth, if nutrients are abundant but the thrifty phenotype adaptations are maintained, the individual might be at greater risk for developing increased fat production and storage. Increased cellular fat in turn produces insulin resistance, which is a common underlying feature of the metabolic syndrome. Such insulin resistance is associated with reduced intracellular signaling of protein kinases that regulate insulin action and lower glucose transporter concentrations in muscle and adipose tissues (65–67). In contrast, increased insulin sensitivity has been shown during early postnatal life in male offspring from protein-malnourished rat dams (67) and lambs that were intrauterine growth restricted (IUGR) from placental growth restriction (20). Taken together, these data (42, 64, 66) indicate that a thrifty response develops in utero and persists during early postnatal life but ultimately leads to impaired insulin action at later stages.

We have developed a model of intrauterine growth restriction induced by placental insufficiency in fetal sheep that replicates all of the fundamental complications found in human pregnancies with marked fetal growth restriction (2, 13, 31, 32, 73, 76, 79, 88), including abnormalities in umbilical artery Doppler velocimetry (69), hypoglycemia, hypoinsulinemia, and hypoxia (57, 70). These fetuses also have reduced β-cell mass and insulin secretion due to decreased rates of β-cell proliferation and insulin biosynthesis in the existing β-cells (53, 55), contributing to the hypoinsulinemia. Despite the hypoglycemia and hypoinsulinemia in these fetuses, however, preliminary observations indicate that insulin sensitivity is increased (55) and proximal insulin-signaling factors in liver and skeletal muscle (insulin receptor substrate-1) are increased (75). However, these preliminary observations have not been confirmed, nor has their impact on fetal glucose metabolism been determined.

Therefore, in this study we measured fetal glucose uptake, utilization, oxidation, and production rates on a body weight-specific basis in IUGR fetal sheep that were nutrient deprived from placental insufficiency (both smaller placental size and reduced glucose and amino acid transport capacity). We also examined fetal glucose metabolism during acute hyperglycemia to determine whether reintroducing glucose could reverse the higher fetal glucose production found in the IUGR fetuses (normal fetal sheep have no measurable glucose production). To evaluate the maintenance of glucose utilization we determined tissue glycogen contents and glucose transporter concentrations. Furthermore, to explain the glucose production in the fetus, we determined the mRNA expression levels for hepatic gluconeogenic enzymes that are activated by phosphorylated cAMP response element-binding (CREB) protein.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Ovine model of intrauterine growth restriction. Pregnant Cheviot ewes carrying singletons were purchased from Ovis (Canton, SD) and managed in compliance with the Institutional Animal Care and Use Committee, University of Colorado Health Sciences Center, at the Perinatal Research Center, Aurora, CO, accredited by the National Institutes of Health, the US Department of Agriculture, and the American Association for Accreditation of Laboratory Animal Care. IUGR fetuses were created by exposing pregnant ewes to elevated ambient temperatures (40°C for 12 h, 35°C for 12 h) from 39 ± 2 days gestation age (dGA; means ± SD) until 96 ± 5 dGA as previously described (53–55, 88). Control fetuses were from pair-fed, gestational age-matched, normal, healthy pregnant ewes maintained at 25°C. Six of seven fetuses in the control treatment group completed in vivo studies. Of the six IUGR fetuses that survived treatment (70% survival rate due to abortion), three had completed in vivo studies. Tissues were collected from all fetuses and examined for protein and RNA expression.

Surgical preparation. At ~125 dGA, fetuses were surgically instrumented with indwelling catheters (22–24, 39, 52, 61). Fetal catheters were placed in the abdominal aorta via hindlimb pedal arteries, umbilical vein, and femoral veins via the saphenous veins. Maternal catheters were placed in the femoral artery and vein. All catheters were subcutaneously tunneled to the ewe's flank and kept in a plastic pouch. Ewes were allowed to recover for 5–7 days after surgery before fetal glucose uptake and metabolism was determined.

Fetal glucose uptake and utilization. Fetal glucose uptake was calculated using the Fick principle and performed in conjunction with D-[14C(U)]glucose (New England Nucleotides; PerkinElmer Life Sciences, Boston, MA) as a glucose tracer to determine rates of glucose utilization and oxidation, as previously reported (23, 39, 40). Briefly, 1 h prior to baseline blood sampling, a bolus of 26.6 µCi 3H2O and 70.6 µCi D-[14C(U)]glucose in saline was administered, followed by a constant infusion of 0.49 µCi/min 3H2O and 1.31 µCi/min D-[14C(U)]glucose. Four arterial and umbilical vein blood samples were collected simultaneously during the basal steady-state period at –35, –25, –15, and –5 min prior to dextrose administration. The hyperglycemic clamp was initiated with a dextrose in water bolus (230 ± 22 mg/kg) into the fetus followed by a constant infusion of 33% dextrose in water to increase and maintain fetal arterial plasma glucose concentrations at 2.3 mmol/l. Fetal arterial plasma samples were collected between 5 and 60 min to clamp the fetal plasma glucose concentration. Fetal blood samples for the hyperglycemic steady-state period were collected at 60, 75, 90, and 105 min from the fetal artery and umbilical vein. Fetal blood concentrations of 3H2O, glucose, radiolabeled glucose, radiolabeled 14CO2, lactate, and oxygen were determined for the arterial and umbilical vein. All calculations were done during steady-state conditions. Umbilical blood flow rate was calculated by the steady-state diffusion technique (23, 39, 59). Umbilical (net fetal) uptake rates of glucose, oxygen, and lactate from the uteroplacenta were calculated using the Fick principle [umbilical blood flow (ml/min) x umbilical venous-arterial substrate concentration difference (mg/ml or mmol/ml)]. During the hyperglycemic period, total fetal glucose uptake rate was calculated as the sum of umbilical (net fetal) glucose uptake rate plus the rate of dextrose infused intravenously into the fetus. Fetal glucose utilization rate (mmol/min) was calculated by dividing the net fetal D-[14C(U)]glucose tracer uptake rate by the fetal arterial-specific activity (dpm/mmol). The net fetal D-[14C(U)]glucose uptake rate was calculated as the rate of D-[14C(U)]glucose intravenous infusion into the fetus (dpm/min) minus the net rate of diffusion of the tracer into the uteroplacenta, calculated as {umbilical blood flow (ml/min) x umbilical D-[14C(U)]glucose arteriovenous concentration difference (dpm/ml)}. Fetal glucose production rate was calculated as the difference between fetal glucose utilization rate and total fetal glucose uptake rate [net umbilical (fetal) glucose uptake rate from the uteroplacenta in the basal period study or this rate plus the rate of intravenous dextrose infusion into the fetus during the hyperglycemic clamp period]. Fetal glucose oxidation rate (mmol/min) was calculated by multiplying the fetal glucose oxidation fraction by the glucose utilization rate. The fetal glucose oxidation fraction (GOxF) was calculated as the net rate of fetal 14CO2 excretion to the uteroplacenta divided by the net fetal uptake rate of D-[14C(U)]glucose. The net rate of 14CO2 flux to the uteroplacenta from the fetus was calculated by multiplying the fetal 14CO2 arteriovenous concentration difference (dpm/ml) by the umbilical blood flow rate (ml/min). All results were normalized to fetal weight (kg) determined at necropsy, which was performed 3–4 h following completion of the in vivo study for all but two fetuses, one from each treatment group. For the two fetuses that were not necropsied on the day of their in vivo study, we calculated the fetal weights for the in vivo study on the basis of weight at necropsy and gestational age according to fetal growth curves established in our laboratory (11).

Biochemical analysis. Blood oxygen saturation and hemoglobin concentrations were measured with an ABL 520 blood gas analyzer (Radiometer, Copenhagen, Denmark). Oxygen content was determined as the product of oxygen saturation and oxygen capacity. The pH, PO2, and hematocrit were determined for 39.1°C using an ABL 520 blood gas analyzer.

Whole blood collected in EDTA-coated syringes was centrifuged (14,000 g) for 3 min at 4°C. Plasma was aspirated from the pelleted red blood cells and stored at –70°C for hormone and amino acid measurements. Plasma glucose and lactate concentrations were measured immediately using a YSI model 2700 Select Biochemistry Analyzer (Yellow Springs Instruments, Yellow Springs, OH). Plasma insulin concentrations were measured by an ovine insulin ELISA (Alpco Diagnostics, Windham, NH).

Glucose transporter immunoblots. Immunoblots for glucose transporter (GLUT)1 and GLUT4 were performed on fetal tissues as previously described (3, 4, 9). Fetal tissues were homogenized in ice-cold lysis buffer containing: 1% Nonidet P-40, 150 mmol/l NaCl, 1 mM EDTA, 1 mmol/l Na3VO4, 1 mmol/l NaF, 50 mmol/l Tris, pH 7.4, 1 mmol/l phenylmethylsulfonyl fluoride (PMSF), 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin. The lysates were centrifuged for 15 min at 12,000 g and pellets discarded. The protein extracts were stored at –80°C for immunoblotting. Protein concentrations were determined with a Bradford DC protein assay (Bio-Rad Laboratories, Richmond, CA) prior to separation.

Equal volumes of Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA) containing 5% β-mercaptoethanol were added to 75 µg of the tissue protein extract and denatured for 5 min at 95°C. Protein extracts were separated by 10% SDS-polyacrylamide gel electrophoresis, (6) transferred to PVDF membrane (BioRad Laboratories), and blocked for 1 h in 5% nonfat dry milk and phosphate-buffered saline with 0.05% Tween 20 (PBST). Immunoblot detection of glucose transporters was accomplished with a rabbit anti-GLUT1 polyclonal antibody (1:5,000; Chemicon International, Temecula, CA) or rabbit anti-GLUT4 polyclonal antibody (1:1,000; Chemicon) in PBST containing 5% nonfat dry milk. Binding of the rabbit antiserum was detected with anti-rabbit immunoglobulin G horseradish peroxidase (HRP)-conjugated secondary antibody (1:10,000; Bio-Rad Laboratories) using enhanced chemiluminesence-Plus (Amersham Pharmacia Biotech, Arlington Heights, IL) according to the manufacturer's instructions and exposed to Kodak X-ray film below film saturation. GLUT1 or GLUT4 immunocomplexes were removed with a 62.5 mmol/l Tris, pH 6.8, 2% SDS, and 100 mmol/l β-mercaptoethanol solution incubate for 30 min at 50°C. Immunodection for GAPDH (Novus Biologicals, Littleton, CO) was performed and used to normalize for loading differences. Densitometry was analyzed with Scion Image software β-version 4.0.2 (Scion, Frederick, MD) and presented as means ± SE.

CREB immunoblots. Immunoblots for CREB and Ser133-phosphorylated CREB were performed as follows. Protein was extracted from pulverized hepatic tissue (200 mg) by the addition of 600 µl of ice-cold lysis buffer [150 mmol/l NaCl, pH 7.4, 20 mmol/l Tris, 1% (vol/vol) Nonidet P-40, 2 mmol/l EDTA, 2.5 mmol/l Na4P2O7, 10% (vol/vol) glycerol, 20 mmol/l β-glycerophosphate, 0.575 mmol/l PMSF, 2% (vol/vol) Sigma mammalian protease inhibitor cocktail, 0.5% (vol/vol) Sigma phosphatase inhibitor] followed by 30 min on an orbital rocker at 4°C. The samples were then sonicated for 30 s, agitated, and placed on an orbital rocker for another 30 min at 4°C. The protein was separated from cellular debris by centrifugation at 21,000 g for 20 min at 4°C. The supernatant was removed and the protein concentration quantified with the Bio-Rad DC protein assay. Protein samples (30 µg) were separated and blots prepared as described for the GLUT proteins. Immunoblot detection was accomplished with rabbit anti-Ser133-phosphorylated CREB (1:500; Cell Signaling Technology, Danvers, MA) in PBST with 5% bovine serum albumin, rabbit anti-CREB (1:1,000; Santa Cruz Biotechnology), and mouse anti-actin (1:40,000; Medimmune, Gaithersburg, MD) in PBST with 5% nonfat dried milk using anti-rabbit IgG or with anti-mouse IgG (1:20,000; Upstate) HRP-conjugated secondary antibodies. Immunocomplexes were visualized and analyzed as described above for the glucose transporters.

Glycogen content. Glycogen content in liver and skeletal muscle was determined as previously described (9, 15). Briefly, 100 mg of hepatic or skeletal muscle tissue was pulverized and digested in 2 ml of 30% KOH at 95°C for 30 min. The homogenate (150 µl) was placed on No. 1 Whatman filter paper and washed in 66% ethanol with constant stirring for 30 min. The filter paper was removed, dried, and cut into small pieces. Glycogen was converted to glucose with 31.1 U amyloglucosidase (Sigma Chemical) in 0.2 M acetate buffer (pH 4.8, 0.5% glacial acetic acid, 0.12 M sodium acetate) at 37°C for 60 min. Glucose concentration of this solution was determined in triplicate on a Yellow Springs analyzer and compared with concurrently run standards of glycogen (Sigma Chemical). Results are expressed as milligrams glycogen per grams tissue (wet weight).

RNA extraction and quantitative real-time PCR. Total RNA from fetal liver was extracted with Tri Reagent (Molecular Research Center, Cincinnati, OH) and cleaned up using a Qiagen Mini RNeasy column (Qiagen, Valencia, CA). Prior to designing quantitative PCR primers against the sheep nucleotide sequences, ovine cDNA clones were generated using primers designed against orthologs and are available upon request. The PCR products were amplified by reverse transcriptase PCR from the polyadenylated RNA using Superscript II reverse transcriptase and Taq polymerase (Invitrogen Life Technologies, Carlsbad, CA) as previously described (51). PCR products were TA cloned using TOPO PCR II kit and transformed into Mach1 T1 phage-resistant, chemically competent E. coli (Invitrogen Life Technologies). Plasmid DNA was purified using QIAprep Spin Miniprep kit (Qiagen, Valencia, CA), and nucleotide sequence was confirmed by sequencing both strands of the cDNA clone. The ovine nucleotide sequences were deposited into GenBank: phosphoenolpyruvate carboxykinase (PEPCK) accession no. EF062862, glucose-6-phosphatase (G-6-Pase) accession no. EF062861, peroxisome proliferator-activated receptor-{gamma} coactivator-1{alpha} (PGC-1{alpha}) accession no. AY957611, and ribosomal protein S15 accession no. AY949774.

For each pair of oligonucleotide primers designed against the sheep nucleotide sequence, the specificity was determined by melting curve analysis, agarose gel electrophoresis, and nucleotide sequencing the PCR product after amplification with SYBR Green PCR master mix (Applied Biosystems, Foster City, CA). PCR efficiency was determined with gene-specific plasmid DNA that was linear over eight orders of magnitudes. Samples were run in triplicate, the results were normalized to the reference gene S15 that was analyzed by the comparative {Delta}CT method (CT gene of interest – CT reference gene), and fold change was determined by the Pfaffl method (56, 72). Standard curves for each gene product also were run concurrently to determine the absolute mass by linear regression analysis.

Statistical analysis. All data are expressed as means ± SE. Period means for each animal were used for comparisons. Statistical analyses for biochemical, hematological, and hormonal values and for glucose flux rates were analyzed by one-way ANOVA, using the general linear means procedure in SAS Proc GLM, and differences separated with a post hoc least significant difference test or Student's t-test (80).


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Fetal and maternal hematological values. Hematological variables for the pregnant ewes and fetuses during the basal control period are shown in Table 1. Fetal blood O2 content and the partial pressure of O2 were lower in the IUGR fetuses, but fetal pH, plasma bicarbonate concentration, and hematocrit were not different. Maternal hematological values for IUGR and control ewes were not different. A greater maternal-fetal arterial difference was found for blood oxygen content in the IUGR animals.


View this table:
[in this window]
[in a new window]

  		Table 1. Fetal and maternal hematological values

 
Fetal plasma glucose, lactate, and insulin concentrations at steady states. Maternal plasma glucose concentrations for IUGR (3.9 ± 0.1 mmol/l) and control (4.1 ± 0.3 mmol/l) ewes were not different. The fetal plasma glucose concentration was 52 ± 7% lower in the IUGR fetuses vs. controls during the basal period (Table 2). Maternal-fetal arterial glucose concentration gradients were greater (P < 0.05) in the IUGR group (3.5 ± 0.1) than in the control group (2.8 ± 0.1). The fetal plasma lactate concentrations were not significantly different between the groups at basal conditions but were 3.5 ± 1.4-fold greater in the IUGR fetuses during the hyperglycemic period. Consistent with experimental design, glucose concentrations increased significantly from the basal concentration during the hyperglycemic period (2.3 ± 0.2-fold for controls, 5.0 ± 1.1-fold for IUGR) to values that were not different between treatment groups.


View this table:
[in this window]
[in a new window]

  		Table 2. Fetal arterial plasma glucose, lactate, and insulin concentrations during steady-state periods

 
Plasma insulin concentrations were 69 ± 6 and 74 ± 11% lower in the IUGR fetus compared with control fetuses at basal and hyperglycemic steady states, respectively (P < 0.05; Table 2). The mean plasma insulin concentration increased 2.4 ± 0.2-fold in the control fetuses during the hyperglycemic period (P < 0.05), whereas only a marginal increase of 1.8 ± 0.5-fold in plasma insulin concentration was found in the IUGR fetuses.

Fetal metabolic fluxes. Net umbilical (fetal) glucose, oxygen, and lactate uptake rates were determined during basal and hyperglycemic steady-state periods (Table 3). During the basal steady-state period, umbilical blood and plasma flow rates were lower in IUGR compared with control fetuses (P < 0.05). Umbilical (fetal) oxygen uptake and umbilical lactate uptake rates were lower in IUGR fetuses. The umbilical glucose uptake rate during the basal period was 33 ± 16% lower (P < 0.05) for the IUGR fetuses, but the fetal body weight-specific glucose utilization rate was not different between groups (Table 3). The difference between the fetal glucose utilization rate and total fetal glucose uptake rate, representing fetal glucose production rate, was positive at 41 ± 2% of fetal glucose utilization in the IUGR fetuses but not different from zero in the control fetuses. The GOxF and glucose oxidation rate (GOxR) in IUGR fetuses were 32 ± 9 and 28 ± 6% less, respectively (each P < 0.05), compared with the control fetuses.


View this table:
[in this window]
[in a new window]

  		Table 3. Fetal blood flows and nutrient flux rates

 
During the hyperglycemic steady-state period, umbilical blood and plasma flow rates were lower (P < 0.06 and P < 0.05, respectively) in the IUGR fetuses compared with control fetuses (Table 3). The net fetal lactate uptake rate was lower in the IUGR fetuses during acute hyperglycemia compared with basal rates and was lower (P < 0.05) than that in the control fetuses. Umbilical oxygen uptake tended (P < 0.06) to be less in the IUGR fetuses and was not different from the basal rates for either treatment group. No differences were found between groups for total net fetal glucose uptake rate (umbilical glucose uptake plus glucose infusion rates), glucose utilization rate (GUR), glucose production rate (GPR), GOxF, or GOxR during the hyperglycemic steady-state period. Total net fetal glucose uptake rate, GUR, and GOxR increased from the basal rates in both IUGR and control fetuses. The administration of glucose decreased the fetal GPR in IUGR fetuses to undetectable levels that were not different from the control fetuses.

Fetal and placental weights at necropsy. After completion of the in vivo study, the pregnant ewes and the fetuses were returned to basal conditions prior to being euthanized and necropsied between 128 and 136 dGA. There were three males and four females in the control group and four males and two females in the IUGR group. The IUGR fetuses and placentas weighed 59 ± 3 (P < 0.001) and 61 ± 3% less (P < 0.01), respectively, than controls.

GLUT concentrations in fetal tissue. GLUT concentrations were determined in the fetal brain, liver, and skeletal muscle (Fig. 1Go). GLUT1 concentrations were significantly higher in IUGR fetal brain tissue compared with controls (P < 0.05). Expression of GLUT1 was not different in fetal liver or skeletal muscle between IUGR and control fetuses. GLUT4 concentrations in skeletal muscle of the IUGR fetuses were not different between groups.


Figure 1
View larger version (22K):
[in this window]
[in a new window]

  		Fig. 1. Glucose transporter (GLUT) concentrations for brain, liver, and skeletal muscle were compared between control fetuses (open bars) and intrauterine growth-restricted (IUGR) fetuses (black bars). Representative GLUT immunoblot complexes for control and IUGR fetal tissues are displayed below the graph. Immunocomplex intensities for the GLUT were normalized to GAPDH intensities and are displayed as %mean of the control fetus ± SE. *Significant increase (P < 0.05) in brain GLUT1 concentration; no other differences between treatment groups were observed in GLUT concentrations.

 
Fetal glycogen content. Glycogen content in skeletal muscle was 2.2 ± 0.2-fold greater (P < 0.01) in the IUGR fetuses compared with control fetuses (Fig. 2). The liver glycogen content was not different between the two groups.


Figure 2
View larger version (9K):
[in this window]
[in a new window]

  		Fig. 2. Fetal tissue glycogen content. The mean glycogen content (±SE) in the liver and skeletal muscle was determined for control (open bars) and IUGR fetuses (black bars). The y-axis is glycogen (mg) per gram of tissue, with the tissue evaluated on the ordinate axis. **Significantly higher content of glycogen in IUGR skeletal muscle compared with control (P < 0.01).

 
Gluconeogenic enzyme transcript expression. G-6-Pase expression in the IUGR fetal liver was 19.4-fold greater (P < 0.01) than in controls (Fig. 3). The PEPCK mRNA content was 9.7-fold greater (P < 0.06) in the IUGR liver compared controls. The PGC-1{alpha} mRNA mean concentration (transcriptional coactivator for gluconeogenic enzymes) was 3.8-fold higher in the IUGR fetal liver, but this difference was not significant.


Figure 3
View larger version (7K):
[in this window]
[in a new window]

  		Fig. 3. Gluconeogenic enzyme mRNA concentrations. Glucose-6-phosphatase (G-6-Pase) and phosphoenolpyruvate carboxykinase (PEPCK) mRNA concentrations were determined in control and IUGR fetal livers by real-time RT-PCR. Individual animal mRNA concentrations relative to ribosomal protein S15 (S15) are plotted for control ({square}) and IUGR (bullet) treatment groups on the x-axis. The mean (±SE) relative RNA concentrations are plotted for controls ({lozenge}) and IUGR ({blacktriangleup}) fetuses.

 
Transactivation of gluconeogenic enzymes occurs when protein kinase A activates CREB by phosphorylation at Ser133. Immunoblot analysis showed that the phosphorylated CREB protein concentration normalized to β-actin was 1.9 ± 0.3-fold higher (P < 0.05) in the IUGR fetal liver compared with control fetal liver. However, in the IUGR fetal liver the total CREB concentrations (CREB normalized to β-actin) were 51 ± 7% of the control fetal liver CREB content. Therefore, the fraction of phosphorylated CREB to total CREB was 4.2 ± 0.7-fold higher in IUGR liver vs. the control fetal liver (P < 0.05; Fig. 4).


Figure 4
View larger version (23K):
[in this window]
[in a new window]

  		Fig. 4. cAMP response element-binding protein (CREB). Immunoblot analysis of CREB and phosphorylated CREB (pCREB) was performed on livers from control (open bars) and IUGR (black bars) fetuses. pCREB normalized to total CREB or β-actin and total CREB relative to β-actin are indicated on the x-axis for each treatment group (±SE). The percentages are relative to control intensities that were determined on the same immunoblot; therefore, the y-axis is expressed as %control. *Significant differences between groups (P < 0.05).

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
In this study we measured glucose metabolism in fetal sheep with placental insufficiency and intrauterine growth restriction to determine whether fetuses with intrauterine growth restriction from nutrient deprivation have greater insulin sensitivity. We found that the fetal body weight-specific rate of glucose utilization was not different between IUGR and control fetuses despite the IUGR fetuses having markedly lower plasma insulin (~70%) and glucose (~50%) concentrations. The same results were found at hyperglycemic states, indicating that insulin sensitivity is increased in IUGR fetuses compared with controls. We cannot exclude an increased tissue glucose uptake capacity in the IUGR fetuses, as they had similar rates of glucose utilization despite lower plasma glucose concentrations and their liver and skeletal muscle non-insulin-sensitive glucose transporter concentrations were maintained at levels not different from control fetuses. Together, therefore, these changes in fetal glucose metabolism demonstrate an increased avidity for glucose uptake and utilization by fetal tissues that helps maintain normal rates of fetal glucose metabolism per whole body weight in the IUGR fetuses that are not different from normal fetuses despite lower rates of glucose supply from the placenta. This adaptation represents a definite example of the thrifty phenotype that Hales and Barker (35, 36) ascribed to metabolic adaptation that can aid survival in the presence of nutrient deprivation.

Fetal glucose utilization rates are dependent on plasma insulin concentrations (22, 28). Importantly, fetal body weight-specific glucose utilization rates in the IUGR fetuses were not different from controls, although insulin concentrations were significantly lower (Table 3). A mathematical (as opposed to biological) model for fetal sheep glucose utilization rates that takes into account insulin and glucose concentrations (40) was used to estimate the expected glucose utilization rate for control and IUGR fetuses. At baseline plasma glucose and insulin concentrations, fetal glucose utilization rates were predicted to be 30.1 µmol·min–1·kg–1 for control fetuses and 16.2 µmol·min–1·kg–1 for IUGR fetuses. Similarly, GUR predictions during the hyperglycemic period for control and IUGR fetuses were 46.8 and 38.1 µmol·min–1·kg–1, respectively. In both the basal and hyperglycemic periods the values of GUR for control fetuses predicted by this mathematical model were comparable to the observed values, whereas values for GUR predicted by the model were lower than observed values in the IUGR fetuses (Table 3). These comparisons between the observed data and the predicted values from the mathematical model indicate that fetuses with chronic placental insufficiency and IUGR exhibit increased insulin sensitivity because the biological response (GUR) was equivalent for basal and glucose-stimulated insulin concentrations that are established by the fetus in response to plasma glucose concentrations. Because our placental insufficiency model of intrauterine growth restriction produces asymmetric fetal growth restriction with reduced body content of skeletal muscle and relatively preserved adipose tissue mass (55), it is likely that the "normal" whole body weight-specific values of insulin action in the IUGR fetuses actually represent even greater values of increased glucose and/or insulin sensitivities in these individual tissues. Experiments to measure insulin action in the IUGR fetal hindlimb, which metabolically consists mostly of skeletal muscle, are underway to test this probability in muscle tissue directly.

We also show that the IUGR fetuses with placental insufficiency had a consistent and relatively large difference between the rate of net fetal glucose uptake from the placenta and their whole body rate of glucose utilization, demonstrating the presence of significant rate of fetal glucose production (Table 3). As shown many times before (39, 40), normal, well-nourished fetal sheep do not exhibit measurable rates of glucose production (Table 3). Fetal glucose production has been demonstrated in fetuses made chronically hypoglycemic by a maternal insulin infusion (23), including the induction of enzymes involved in gluconeogenesis (61). However, the induction of gluconeogenic enzymes in the chronically hypoglycemic fetuses by maternal insulin administration was not the result of elevated fetal plasma glucagon or catecholamine concentrations (52). Together, our current data in the IUGR fetuses and the literature reports for hypoglycemic fetuses indicate that chronic hypoglycemia stimulates hepatic glucose production in the fetus, but the mechanism for induction differs between the two experimental models. The response in the hypoglycemic fetuses appears to result from increased fetal cortisol secretion and plasma concentrations (29) found in these fetuses (Rozance PJ, Limesand SW, and Hay WW Jr, unpublished results).

Increased plasma concentrations of the catabolic hormones glucagon and catecholamines, but not cortisol, have been found (55) in IUGR fetuses produced by placental insufficiency. Along with lower plasma insulin concentrations and relative hypoglycemia, the hormonal milieu in the IUGR fetuses in this study supports increased hepatic glucose production via gluconeogenesis (5, 21, 85). We also show enhanced mRNA expression of hepatic gluconeogenic enzymes PEPCK and G-6-Pase in the livers of the IUGR fetuses. Furthermore, the results indicate that the stimulation of these genes may be mediated through CREB, which transactivates PEPCK and G-6-Pase genes (7, 38, 87). Glucagon and catecholamines via their G protein-coupled receptors stimulate the adenylate cyclase pathway to phosphorylate CREB (7, 38). Surprisingly, only a marginal increase in PGC-1{alpha} was found in the IUGR fetal livers because PGC-1{alpha} expression also can be enhanced by phosphorylated CREB (43, 93). PGC-1{alpha} subsequently stimulates PEPCK and G-6-Pase transcription; however, PGC-1{alpha} is not required for PEPCK promoter induction but amplifies the basal and hormone-induced expression of these gluconeogenic enzymes (43, 44, 93). Therefore, the induction of PEPCK and G-6-Pase in the fetus might be less robust than the adult, but there is still a significant induction of gluconeogenic enzymes that is sufficient to promote markedly high rates of fetal glucose production.

Glucagon probably has little effect alone, because pharmacological concentrations of glucagon are required to induce glucose production in fetal sheep (21, 85). Effects of increased plasma norepinephrine concentrations are mixed, as norepinephrine increases plasma glucose concentrations in fetal sheep, which in turn reduces transplacental transport of glucose as well as inhibits insulin secretion and lowers plasma insulin concentrations (27, 46, 47, 82). However, induction of hepatic glycogenolysis occurs with norepinephrine in adult animals (16, 83), but hepatic tissue is less responsive to norepinephrine than epinephrine (17), which could partially contribute to the maintained liver glycogen content in the IUGR fetuses despite the lower glucose and insulin concentrations (Fig. 2). Additionally, norepinephrine acts on extrahepatic tissues to provide gluconeogenic substrates from hepatic glucose production, thereby potentially inducing the Cori cycle in the IUGR fetuses. Such changes in fetal metabolism from increased norepinephrine or epinephrine were reversed by infusing insulin into sheep fetuses (10), indicating that the primary role for catecholamines is to inhibit insulin release. Glucose production from gluconeogenesis rather than glycogenolysis is expected in the IUGR fetuses because glycogen contents remain unchanged or even increase (Fig. 2). Together, our results and such observations reported in the literature from other studies show that the combination of chronic effects of hypoglycemia, low insulin concentrations, and increased glucagon and norepinephrine concentrations lead to the induction of gluconeogenesis, but not glycogenolysis, in IUGR sheep fetuses with placental insufficiency.

Increased insulin sensitivity to glucose as shown in these IUGR fetuses might promote glucose storage as glycogen. We observed selective regulation for hepatic gluconeogenesis pathways that preserved glycogen storage but did not augment it, although we show that fetal insulin sensitivity is increased (Fig. 2). An explanation for the discordant tissue glycogen content in these IUGR fetuses was shown in another data set of IUGR fetuses (75) where glycogen synthase kinase-3β (GSK-3β) was suppressed in the liver. Phosphorylation of GSK-3β by insulin leads to its subsequent phosphorylation and inactivation of glycogen synthase. Lowering GSK-3β, therefore, will favor glycogen synthesis in the fetal liver and consequently maintain glycogen stores. In contrast, the skeletal muscle in the IUGR fetuses showed enhanced insulin sensitivity through proximal signaling by increased insulin receptor protein coupled with decreased levels of insulin signal transduction inhibitors, such as the p85{alpha} regulatory subunit of phosphatidylinositol 3-kinase, which would have the effect of enhancing insulin action to promote glycogen deposition (75). It has recently been shown (14, 48) that adrenalin synergizes with insulin to activate protein kinase B (Akt), which subsequently inactivates GSK-3β, thereby promoting glycogen synthesis and further explaining the increased skeletal muscle glycogen content. Indeed, studies in the ovine IUGR fetal myocardium (9) also document increased weight-specific glycogen concentrations in IUGR fetuses along with greater GLUT4 protein and higher insulin receptor concentrations.

Previous studies of maternal insulin infusions leading to fetal hypoglycemia (19) reported a decline in brain GLUT3, an increase in brain GLUT1, and a subsequent decline in liver GLUT1 but no significant reduction in insulin-sensitive myocardial, skeletal muscle, and adipose tissue GLUT1 or GLUT4 concentrations compared with gestational age-matched sham controls. Similar patterns for GLUT1 and GLUT4 were found in fetuses with placental insufficiency and intrauterine growth restriction in the present study (Fig. 1), where GLUT1 was upregulated in an insulin-independent tissue (brain) and did not differ from controls in insulin-responsive tissues (liver and skeletal muscle). Preliminary data from these tissues (75) suggest that insulin sensitivity is increased through the proximal insulin-signaling cascade. Regardless of mechanisms, such adaptive responses allow the fetus to preserve essential metabolic functions (i.e., oxidative metabolism) at the expense of its growth, which in this paradigm progressively slows during the final one-third of gestation as placental size and total nutrient supply become limiting (89–91).

It also is important to note that many models of intrauterine growth restriction have been developed using vastly different methods to produce placental insufficiency (26, 30, 33, 49, 50, 60, 71, 78, 81, 84). In human pregnancies, intrauterine growth restriction is a frequent and serious complication. It has several known causes, but placental dysfunction is a major contributor leading to fetal nutrient deficiencies and a slower rate of growth (18, 34, 45, 63). In addition to fetal nutrient deficits, complications from placental dysfunction in human IUGR pregnancies include lower placental mass, lower rates of oxygen, amino acid, and glucose uptake by the fetus, and lower rates of umbilical venous blood flow (25, 41, 57, 68–70, 77). Clinical severity of human IUGR fetuses is determined by abnormalities in umbilical artery Doppler velocimetry (69), which is associated with an increased incidence of fetal hypoglycemia and hypoxia (57, 70). Very few animal models recapitulate all of the complications observed in human pregnancies with placental insufficiency and intrauterine growth restriction. However, our ovine model of placental insufficiency and intrauterine growth restriction, established by exposing pregnant ewes to a warm environment, as occurs naturally in warmer microclimates in all of the equatorial regions around the world, replicates all of the complications found in human pregnancies with moderate to even severe fetal growth restriction (2, 13, 31, 32, 74, 79, 88).

Importantly, at least two other experimental IUGR models in sheep with placental insufficiency have been developed. The uterine carunculectomy model (1) produces smaller placentas by surgically ablating the endometrial placental implantation sites (uterine caruncules) prior to pregnancy, thereby reducing the endometrial surface area into which the fetal trophoblast can invade. In addition, the overfed adolescent pregnant ewe model has a smaller placenta but no specific nutrient transport defects (90, 92). This model is produced by overfeeding adolescent ewes that are very early in their adolescent growth phase and have hormonally induced estrus and embryo transfer to initiate and establish, respectively, their pregnancies. Importantly, both of these models, which are markedly different from each other and from our placental insufficiency model, produce offspring (the fetus in the adolescent pregnant ewe model and lambs in the uterine carunculectomy model) that have evidence of increased insulin sensitivity and glucose uptake capacity as in our model (20, 90) in which placental size and transport capacity for glucose and selected amino acids are reduced. Therefore, the IUGR sheep fetus with placental insufficiency appears to have a common phenotype, regardless of how the smaller placenta is experimentally produced or whether or not the placenta is just smaller or also has selective nutrient transport defects, and thus provides a valuable model to evaluate fetal adaptations to nutrient restriction and related postnatal outcomes. As such, it is also an excellent model for studying in utero metabolic programming in mammals.

In terms of programming, it appears that IUGR fetuses produced by placental insufficiency and nutrient deprivation adapt to the hypoglycemic environment in utero by developing mechanisms that maintain or promote tissue glucose uptake and utilization. Teleologically, such adaptive mechanisms to maintain fetal energy stores help ensure fetal survival and, in terms of increased glycogen and fat stores, might help with postnatal survival as well. However, such mechanisms, if they persist, also might affect later developmental and adaptive conditions, and these adaptations might not always be beneficial in the long term. Thus, if the maintained or upregulated mechanisms of insulin sensitivity persist, IUGR fetuses might be predisposed to increased fat deposition when exposed to high-sugar and high-fat diets later in life. For example, the carunclectomy model of IUGR in sheep (20) develops increased insulin action that promotes utilization of both glucose and free fatty acids and increases visceral adiposity in young lambs at 1 mo of age. In addition, human IUGR infants demonstrate increased insulin-induced glucose disposal as early as 48 h after birth (12, 58). Therefore, the common phenotype in fetal sheep, in which IUGR is produced by very different methods, and human IUGR infants provides reasonable support for the hypothesis that placental nutrient insufficiency leads to common metabolic adaptations that will, if not treated properly, lead to later-life pathology. These observations strengthen the case that postnatal nutrition must be matched to the infant's growth rate if a leaner and thus potentially healthier development is to occur.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported by grants from the National Institutes of Health [HD-42815, W. W. Hay, Jr., principal investigator (PI)]. S. W. Limesand (PI) was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant KO1-DK-067393. P. J. Rozance and D. Smith were supported by National Institute of Child Health and Human Development Institutional Training Grant HD-07186 (W. W. Hay, Jr., PI).


   FOOTNOTES
 

Address for reprint requests and other correspondence: S. W. Limesand, Agricultural Research Complex, Dept. of Animal Sciences, Univ. of Arizona, 4101 N. Campbell Ave., Tucson, AZ 85719 (e-mail: Limesand{at}Ag.Arizona.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Alexander G. Studies on the placenta of the sheep (Ovis aries). Effect of surgical reduction in the number of caruncles. J Reprod Fertil 7: 307–322, 1964.[Medline]
  2. Anderson AH, Fennessey PV, Meschia G, Wilkening RB, Battaglia FC. Placental transport of threonine and its utilization in the normal and growth-restricted fetus. Am J Physiol Endocrinol Metab 272: E892–E900, 1997.[Abstract/Free Full Text]
  3. Anderson MS, He J, Flowers-Ziegler J, Devaskar SU, Hay WW Jr. Effects of selective hyperglycemia and hyperinsulinemia on glucose transporters in fetal ovine skeletal muscle. Am J Physiol Regul Integr Comp Physiol 281: R1256–R1263, 2001.[Abstract/Free Full Text]
  4. Anderson MS, Thamotharan M, Kao D, Devaskar SU, Qiao L, Friedman JE, Hay WW Jr. Effects of acute hyperinsulinemia on insulin signal transduction and glucose transporters in ovine fetal skeletal muscle. Am J Physiol Regul Integr Comp Physiol 288: R473–R481, 2005.[Abstract/Free Full Text]
  5. Apatu RS, Barnes RJ. Release of glucose from the liver of fetal and postnatal sheep by portal vein infusion of catecholamines or glucagon. J Physiol 436: 449–468, 1991.[Abstract/Free Full Text]
  6. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. Current Protocols in Molecular Biology. New York: John Wiley and Sons, 1995.
  7. Bady I, Zitoun C, Guignot L, Mithieux G. Activation of liver G-6-Pase in response to insulin-induced hypoglycemia or epinephrine infusion in the rat. Am J Physiol Endocrinol Metab 282: E905–E910, 2002.[Abstract/Free Full Text]
  8. Barker DJP. Mother, Babies and Health in Later Life. Edinburgh, UK: Churchill Livingston, 1998.
  9. Barry JS, Davidsen ML, Limesand SW, Galan HL, Friedman JE, Regnault TR, Hay WW Jr. Developmental changes in ovine myocardial glucose transporters and insulin signaling following hyperthermia-induced intrauterine fetal growth restriction. Exp Biol Med (Maywood) 231: 566–575, 2006.[Abstract/Free Full Text]
  10. Bassett JM, Hanson C. Prevention of hypoinsulinemia modifies catecholamine effects in fetal sheep. Am J Physiol Regul Integr Comp Physiol 278: R1171–R1181, 2000.[Abstract/Free Full Text]
  11. Battaglia FC, Meschia G. An Introduction to Fetal Physiology. London, UK: Academic, 1986.
  12. Bazaes RA, Alegria A, Pittaluga E, Avila A, Iniguez G, Mericq V. Determinants of insulin sensitivity and secretion in very-low-birth-weight children. J Clin Endocrinol Metab 89: 1267–1272, 2004.[Abstract/Free Full Text]
  13. Bell AW, Wilkening RB, Meschia G. Some aspects of placental function in chronically heat-stressed ewes. J Dev Physiol 9: 17–29, 1987.[Web of Science][Medline]
  14. Brennesvik EO, Ktori C, Ruzzin J, Jebens E, Shepherd PR, Jensen J. Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline. Cell Signal 17: 1551–1559, 2005.[CrossRef][Web of Science][Medline]
  15. Chan TM, Young KM, Hutson NJ, Brumley FT, Exton JH. Hepatic metabolism of genetically diabetic (db/db) mice. I. Carbohydrate metabolism. Am J Physiol 229: 1702–1712, 1975.[Abstract/Free Full Text]
  16. Chu CA, Sindelar DK, Igawa K, Sherck S, Neal DW, Emshwiller M, Cherrington AD. The direct effects of catecholamines on hepatic glucose production occur via {alpha}1- and β2-receptors in the dog. Am J Physiol Endocrinol Metab 279: E463–E473, 2000.[Abstract/Free Full Text]
  17. Connolly CC, Steiner KE, Stevenson RW, Neal DW, Williams PE, Alberti KG, Cherrington AD. Regulation of glucose metabolism by norepinephrine in conscious dogs. Am J Physiol Endocrinol Metab 261: E764–E772, 1991.[Abstract/Free Full Text]
  18. Creasy RK, Resnik R. Intrauterine growth restriction. In: Maternal-Fetal Medicine, edited by Creasy RK and Resnik R. Philadelphia, PA: W. B. Saunders, 1999, p. 569–584.
  19. Das UG, Schroeder RE, Hay WW Jr, Devaskar SU. Time-dependent and tissue-specific effects of circulating glucose on fetal ovine glucose transporters. Am J Physiol Regul Integr Comp Physiol 276: R809–R817, 1999.[Abstract/Free Full Text]
  20. De Blasio MJ, Gatford KL, McMillen IC, Robinson JS, Owens JA. Placental restriction of fetal growth increases insulin action, growth, and adiposity in the young lamb. Endocrinology 148: 1350–1358, 2007.[Abstract/Free Full Text]
  21. Devaskar SU, Ganguli S, Styer D, Devaskar UP, Sperling MA. Glucagon and glucose dynamics in sheep: evidence for glucagon resistance in the fetus. Am J Physiol Endocrinol Metab 246: E256–E265, 1984.[Abstract/Free Full Text]
  22. DiGiacomo JE, Hay WW Jr. Effect of hypoinsulinemia and hyperglycemia on fetal glucose utilization. Am J Physiol Endocrinol Metab 259: E506–E512, 1990.[Abstract/Free Full Text]
  23. DiGiacomo JE, Hay WW Jr. Fetal glucose metabolism and oxygen consumption during sustained hypoglycemia. Metabolism 39: 193–202, 1990.[CrossRef][Web of Science][Medline]
  24. DiGiacomo JE, Hay WW Jr. Placental-fetal glucose exchange and placental glucose consumption in pregnant sheep. Am J Physiol Endocrinol Metab 258: E360–E367, 1990.[Abstract/Free Full Text]
  25. Ferrazzi E, Rigano S, Bozzo M, Bellotti M, Giovannini N, Galan H, Battaglia FC. Umbilical vein blood flow in growth-restricted fetuses. Ultrasound Obstet Gynecol 16: 432–438, 2000.[CrossRef][Web of Science][Medline]
  26. Ford SP, Hess BW, Schwope MM, Nijland MJ, Gilbert JS, Vonnahme KA, Means WJ, Han H, Nathanielsz PW. Maternal undernutrition during early to mid-gestation in the ewe results in altered growth, adiposity, and glucose tolerance in male offspring. J Anim Sci 85: 1285–1294, 2007.[Abstract/Free Full Text]
  27. Fowden AL. Effects of adrenaline and amino acids on the release of insulin in the sheep fetus. J Endocrinol 87: 113–121, 1980.[Abstract/Free Full Text]
  28. Fowden AL, Hay WW Jr. The effects of pancreatectomy on the rates of glucose utilization, oxidation and production in the sheep fetus. Q J Exp Physiol 73: 973–984, 1988.[Abstract/Free Full Text]
  29. Fowden AL, Mundy L, Silver M. Developmental regulation of glucogenesis in the sheep fetus during late gestation. J Physiol 508: 937–947, 1998.[Abstract/Free Full Text]
  30. Gagnon R, Challis J, Johnston L, Fraher L. Fetal endocrine responses to chronic placental embolization in the late-gestation ovine fetus. Am J Obstet Gynecol 170: 929–938, 1994.[Web of Science][Medline]
  31. Galan HL, Anthony RV, Rigano S, Parker TA, de Vrijer B, Ferrazzi E, Wilkening RB, Regnault TR. Fetal hypertension and abnormal Doppler velocimetry in an ovine model of intrauterine growth restriction. Am J Obstet Gynecol 192: 272–279, 2005.[CrossRef][Web of Science][Medline]
  32. Galan HL, Hussey MJ, Barbera A, Ferrazzi E, Chung M, Hobbins JC, Battaglia FC. Relationship of fetal growth to duration of heat stress in an ovine model of placental insufficiency. Am J Obstet Gynecol 180: 1278–1282, 1999.[CrossRef][Web of Science][Medline]
  33. Garofano A, Czernichow P, Breant B. In utero undernutrition impairs rat beta-cell development. Diabetologia 40: 1231–1234, 1997.[CrossRef][Web of Science][Medline]
  34. Godfrey KM, Hales CN, Osmond C, Barker DJ, Taylor KP. Relation of cord plasma concentrations of proinsulin, 32–33 split proinsulin, insulin and C-peptide to placental weight and the baby's size and proportions at birth. Early Hum Dev 46: 129–140, 1996.[CrossRef][Web of Science][Medline]
  35. Hales CN, Barker DJ. The thrifty phenotype hypothesis. Br Med Bull 60: 5–20, 2001.[Abstract/Free Full Text]
  36. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 35: 595–601, 1992.[CrossRef][Web of Science][Medline]
  37. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C, Winter PD. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 303: 1019–1022, 1991.[Abstract/Free Full Text]
  38. Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 66: 581–611, 1997.[CrossRef][Web of Science][Medline]
  39. Hay WW Jr, DiGiacomo JE, Meznarich HK, Hirst K, Zerbe G. Effects of glucose and insulin on fetal glucose oxidation and oxygen consumption. Am J Physiol Endocrinol Metab 256: E704–E713, 1989.[Abstract/Free Full Text]
  40. Hay WW Jr, Meznarich HK, DiGiacomo JE, Hirst K, Zerbe G. Effects of insulin and glucose concentrations on glucose utilization in fetal sheep. Pediatr Res 23: 381–387, 1988.[Web of Science][Medline]
  41. Heinonen S, Taipale P, Saarikoski S. Weights of placentae from small-for-gestational age infants revisited. Placenta 22: 399–404, 2001.[CrossRef][Web of Science][Medline]
  42. Hermann TS, Rask-Madsen C, Ihlemann N, Dominguez H, Jensen CB, Storgaard H, Vaag AA, Kober L, Torp-Pedersen C. Normal insulin-stimulated endothelial function and impaired insulin-stimulated muscle glucose uptake in young adults with low birth weight. J Clin Endocrinol Metab 88: 1252–1257, 2003.[Abstract/Free Full Text]
  43. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Puigserver P, Spiegelman B, Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413: 179–183, 2001.[CrossRef][Medline]
  44. Herzog B, Hall RK, Wang XL, Waltner-Law M, Granner DK. Peroxisome proliferator-activated receptor gamma coactivator-1alpha, as a transcription amplifier, is not essential for basal and hormone-induced phosphoenolpyruvate carboxykinase gene expression. Mol Endocrinol 18: 807–819, 2004.[Abstract/Free Full Text]
  45. Hubinont C, Nicolini U, Fisk NM, Tannirandorn Y, Rodeck CH. Endocrine pancreatic function in growth-retarded fetuses. Obstet Gynecol 77: 541–544, 1991.[Web of Science][Medline]
  46. Jackson BT, Cohn HE, Morrison SH, Baker RM, Piasecki GJ. Hypoxia-induced sympathetic inhibition of the fetal plasma insulin response to hyperglycemia. Diabetes 42: 1621–1625, 1993.[Abstract]
  47. Jackson BT, Piasecki GJ, Cohn HE, Cohen WR. Control of fetal insulin secretion. Am J Physiol Regul Integr Comp Physiol 279: R2179–R2188, 2000.[Abstract/Free Full Text]
  48. Jensen J, Brennesvik EO, Lai YC, Shepherd PR. GSK-3beta regulation in skeletal muscles by adrenaline and insulin: evidence that PKA and PKB regulate different pools of GSK-3. Cell Signal 19: 204–210, 2007.[CrossRef][Web of Science][Medline]
  49. Lang U, Baker RS, Braems G, Zygmunt M, Kunzel W, Clark KE. Uterine blood flow—a determinant of fetal growth. Eur J Obstet Gynecol Reprod Biol 110, Suppl 1: S55–S61, 2003.[CrossRef][Web of Science][Medline]
  50. Lang U, Baker RS, Khoury J, Clark KE. Effects of chronic reduction in uterine blood flow on fetal and placental growth in the sheep. Am J Physiol Regul Integr Comp Physiol 279: R53–R59, 2000.[Abstract/Free Full Text]
  51. Limesand SW, Anthony RV. Novel activator protein-2alpha splice-variants function as transactivators of the ovine placental lactogen gene. Eur J Biochem 268: 2390–2401, 2001.[Web of Science][Medline]
  52. Limesand SW, Hay WW Jr. Adaptation of ovine fetal pancreatic insulin secretion to chronic hypoglycaemia and euglycaemic correction. J Physiol 547: 95–105, 2002.[CrossRef][Web of Science][Medline]
  53. Limesand SW, Jensen J, Hutton JC, Hay WW Jr. Diminished β-cell replication contributes to reduced β-cell mass in fetal sheep with intrauterine growth restriction. Am J Physiol Regul Integr Comp Physiol 288: R1297–R1305, 2005.[Abstract/Free Full Text]
  54. Limesand SW, Regnault TR, Hay WW Jr. Characterization of glucose transporter 8 (GLUT8) in the ovine placenta of normal and growth restricted fetuses. Placenta 25: 70–77, 2004.[CrossRef][Web of Science][Medline]
  55. Limesand SW, Rozance PJ, Zerbe GO, Hutton JC, Hay WW Jr. Attenuated insulin release and storage in fetal sheep pancreatic islets with intrauterine growth restriction. Endocrinology 147: 1488–1497, 2006.[Abstract/Free Full Text]
  56. Liu W, Saint DA. A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal Biochem 302: 52–59, 2002.[CrossRef][Web of Science][Medline]
  57. Marconi AM, Paolini CL, Stramare L, Cetin I, Fennessey PV, Pardi G, Battaglia FC. Steady state maternal-fetal leucine enrichments in normal and intrauterine growth-restricted pregnancies. Pediatr Res 46: 114–119, 1999.[Web of Science][Medline]
  58. Mericq V, Ong KK, Bazaes R, Pena V, Avila A, Salazar T, Soto N, Iniguez G, Dunger DB. Longitudinal changes in insulin sensitivity and secretion from birth to age three years in small- and appropriate-for-gestational-age children. Diabetologia 48: 2609–2614, 2005.[CrossRef][Web of Science][Medline]
  59. Meschia G, Cotter JR, Breathnach CS, Barron DH. Simultaneous measurement of uterine and umbilical blood flows and oxygen uptake. Q J Exp Physiol 52: 1–8, 1967.[Abstract/Free Full Text]
  60. Mostello D, Chalk C, Khoury J, Mack CE, Siddiqi TA, Clark KE. Chronic anemia in pregnant ewes: maternal and fetal effects. Am J Physiol Regul Integr Comp Physiol 261: R1075–R1083, 1991.[Abstract/Free Full Text]
  61. Narkewicz MR, Carver TD, Hay WW Jr. Induction of cytosolic phosphoenolpyruvate carboxykinase in the ovine fetal liver by chronic fetal hypoglycemia and hypoinsulinemia. Pediatr Res 33: 493–496, 1993.[Web of Science][Medline]
  62. Newsome CA, Shiell AW, Fall CH, Phillips DI, Shier R, Law CM. Is birth weight related to later glucose and insulin metabolism?—A systematic review. Diabet Med 20: 339–348, 2003.[CrossRef][Web of Science][Medline]
  63. Nicolini U, Hubinont C, Santolaya J, Fisk NM, Rodeck CH. Effects of fetal intravenous glucose challenge in normal and growth retarded fetuses. Horm Metab Res 22: 426–430, 1990.[Web of Science][Medline]
  64. Owens JA, Thavaneswaran P, De Blasio MJ, McMillen IC, Robinson JS, Gatford KL. Sex-specific effects of placental restriction on components of the metabolic syndrome in young adult sheep. Am J Physiol Endocrinol Metab 292: E1879–E1889, 2007.[Abstract/Free Full Text]
  65. Ozanne SE, Jensen CB, Tingey KJ, Martin-Gronert MS, Grunnet L, Brons C, Storgaard H, Vaag AA. Decreased protein levels of key insulin signalling molecules in adipose tissue from young men with a low birthweight: potential link to increased risk of diabetes? Diabetologia 49: 2993–2999, 2006.[CrossRef][Web of Science][Medline]
  66. Ozanne SE, Jensen CB, Tingey KJ, Storgaard H, Madsbad S, Vaag AA. Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. Diabetologia 48: 547–552, 2005.[CrossRef][Web of Science][Medline]
  67. Ozanne SE, Wang CL, Coleman N, Smith GD. Altered muscle insulin sensitivity in the male offspring of protein-malnourished rats. Am J Physiol Endocrinol Metab 271: E1128–E1134, 1996.[Abstract/Free Full Text]
  68. Paolini CL, Marconi AM, Ronzoni S, Di Noio M, Fennessey PV, Pardi G, Battaglia FC. Placental transport of leucine, phenylalanine, glycine, and proline in intrauterine growth-restricted pregnancies. J Clin Endocrinol Metab 86: 5427–5432, 2001.[Abstract/Free Full Text]
  69. Pardi G, Cetin I, Marconi AM, Bozzetti P, Buscaglia M, Makowski EL, Battaglia FC. Venous drainage of the human uterus: respiratory gas studies in normal and fetal growth-retarded pregnancies. Am J Obstet Gynecol 166: 699–706, 1992.[Web of Science][Medline]
  70. Pardi G, Cetin I, Marconi AM, Lanfranchi A, Bozzetti P, Ferrazzi E, Buscaglia M, Battaglia FC. Diagnostic value of blood sampling in fetuses with growth retardation. N Engl J Med 328: 692–696, 1993.[Abstract/Free Full Text]
  71. Petrik J, Reusens B, Arany E, Remacle C, Coelho C, Hoet JJ, Hill DJ. A low protein diet alters the balance of islet cell replication and apoptosis in the fetal and neonatal rat and is associated with a reduced pancreatic expression of insulin-like growth factor-II. Endocrinology 140: 4861–4873, 1999.[Abstract/Free Full Text]
  72. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.[Abstract/Free Full Text]
  73. Regnault TR, de Vrijer B, Galan HL, Davidsen ML, Trembler KA, Battaglia FC, Wilkening RB, Anthony RV. The relationship between transplacental O2 diffusion and placental expression of PlGF, VEGF and their receptors in a placental insufficiency model of fetal growth restriction. J Physiol 550: 641–656, 2003.[Abstract/Free Full Text]
  74. Regnault TR, de Vrijer B, Galan HL, Wilkening RB, Battaglia FC, Meschia G. Development and mechanisms of fetal hypoxia in severe fetal growth restriction. Placenta 28: 714–723, 2007.[CrossRef][Web of Science][Medline]
  75. Regnault TR, Friedman JE, Wilkening RB, Anthony RV, Hay WW Jr. Fetoplacental transport and utilization of amino acids in IUGR—a review. Placenta 26, Suppl A: S52–S62, 2005.[CrossRef][Web of Science][Medline]
  76. Regnault TR, Orbus RJ, de Vrijer B, Davidsen ML, Galan HL, Wilkening RB, Anthony RV. Placental expression of VEGF, PlGF and their receptors in a model of placental insufficiency-intrauterine growth restriction (PI-IUGR). Placenta 23: 132–144, 2002.[CrossRef][Web of Science][Medline]
  77. Rigano S, Bozzo M, Ferrazzi E, Bellotti M, Battaglia FC, Galan HL. Early and persistent reduction in umbilical vein blood flow in the growth-restricted fetus: a longitudinal study. Am J Obstet Gynecol 185: 834–838, 2001.[CrossRef][Web of Science][Medline]
  78. Robinson JS, Kingston EJ, Jones CT, Thorburn GD. Studies on experimental growth retardation in sheep. The effect of removal of a endometrial caruncles on fetal size and metabolism. J Dev Physiol 1: 379–398, 1979.[Medline]
  79. Ross JC, Fennessey PV, Wilkening RB, Battaglia FC, Meschia G. Placental transport and fetal utilization of leucine in a model of fetal growth retardation. Am J Physiol Endocrinol Metab 270: E491–E503, 1996.[Abstract/Free Full Text]
  80. SAS Institute. SAS/STAT User's Guide. Cary, NC: SAS Institute, 1999.
  81. Simmons RA, Templeton LJ, Gertz SJ. Intrauterine growth retardation leads to the development of type 2 diabetes in the rat. Diabetes 50: 2279–2286, 2001.[Abstract/Free Full Text]
  82. Sperling MA, Christensen RA, Ganguli S, Anand R. Adrenergic modulation of pancreatic hormone secretion in utero: studies in fetal sheep. Pediatr Res 14: 203–208, 1980.[Web of Science][Medline]
  83. Stratford LL, Hooper SB. Effect of hypoxemia on tissue glycogen content and glycolytic enzyme activities in fetal sheep. Am J Physiol Regul Integr Comp Physiol 272: R103–R110, 1997.[Abstract/Free Full Text]
  84. Symonds ME, Pearce S, Bispham J, Gardner DS, Stephenson T. Timing of nutrient restriction and programming of fetal adipose tissue development. Proc Nutr Soc 63: 397–403, 2004.[CrossRef][Web of Science][Medline]
  85. Teng C, Battaglia FC, Meschia G, Narkewicz MR, Wilkening RB. Fetal hepatic and umbilical uptakes of glucogenic substrates during a glucagon-somatostatin infusion. Am J Physiol Endocrinol Metab 282: E542–E550, 2002.[Abstract/Free Full Text]
  86. Thiel G, Al SJ, Stefano L. cAMP response element binding protein (CREB) activates transcription via two distinct genetic elements of the human glucose-6-phosphatase gene. BMC Mol Biol 6: 2, 2005.[CrossRef][Medline]
  87. Thureen PJ, Trembler KA, Meschia G, Makowski EL, Wilkening RB. Placental glucose transport in heat-induced fetal growth retardation. Am J Physiol Regul Integr Comp Physiol 263: R578–R585, 1992.[Abstract/Free Full Text]
  88. Wallace JM. Nutrient partitioning during pregnancy: adverse gestational outcome in overnourished adolescent dams. Proc Nutr Soc 59: 107–117, 2000.[Web of Science][Medline]
  89. Wallace JM, Bourke DA, Aitken RP, Leitch N, Hay WW Jr. Blood flows and nutrient uptakes in growth-restricted pregnancies induced by overnourishing adolescent sheep. Am J Physiol Regul Integr Comp Physiol 282: R1027–R1036, 2002.[Abstract/Free Full Text]
  90. Wallace JM, Bourke DA, Aitken RP, Palmer RM, Da SP, Cruickshank MA. Relationship between nutritionally-mediated placental growth restriction and fetal growth, body composition and endocrine status during late gestation in adolescent sheep. Placenta 21: 100–108, 2000.[CrossRef][Web of Science][Medline]
  91. Wallace JM, Regnault TR, Limesand SW, Hay WW Jr, Anthony RV. Investigating the causes of low birth weight in contrasting ovine paradigms. J Physiol 565: 19–26, 2005.[Abstract/Free Full Text]
  92. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, Spiegelman BM. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413: 131–138, 2001.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. W. Limesand, P. J. Rozance, L. D. Brown, and W. W. Hay Jr.
Effects of chronic hypoglycemia and euglycemic correction on lysine metabolism in fetal sheep
Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E879 - E887.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
P. J. Rozance, S. W. Limesand, J. S. Barry, L. D. Brown, S. R. Thorn, D. LoTurco, T. R. H. Regnault, J. E. Friedman, and W. W. Hay Jr.
Chronic late-gestation hypoglycemia upregulates hepatic PEPCK associated with increased PGC1{alpha} mRNA and phosphorylated CREB in fetal sheep
Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E365 - E370.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/6/E1716    most recent
00459.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Limesand, S. W.
Right arrow Articles by Hay, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Limesand, S. W.
Right arrow Articles by Hay, W. W., Jr.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.